- Home
- OKYO vs DYAI Comparison
OKYO vs DYAI Comparison
Compare OKYO & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- DYAI
- Stock Information
- Founded
- OKYO 2007
- DYAI 1979
- Country
- OKYO United Kingdom
- DYAI United States
- Employees
- OKYO N/A
- DYAI N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OKYO Health Care
- DYAI Health Care
- Exchange
- OKYO Nasdaq
- DYAI Nasdaq
- Market Cap
- OKYO 37.0M
- DYAI 31.3M
- IPO Year
- OKYO 2022
- DYAI 2004
- Fundamental
- Price
- OKYO $1.86
- DYAI $0.97
- Analyst Decision
- OKYO Strong Buy
- DYAI Strong Buy
- Analyst Count
- OKYO 1
- DYAI 1
- Target Price
- OKYO $7.00
- DYAI $6.00
- AVG Volume (30 Days)
- OKYO 163.5K
- DYAI 37.8K
- Earning Date
- OKYO 06-13-2025
- DYAI 05-14-2025
- Dividend Yield
- OKYO N/A
- DYAI N/A
- EPS Growth
- OKYO N/A
- DYAI N/A
- EPS
- OKYO N/A
- DYAI N/A
- Revenue
- OKYO N/A
- DYAI $3,554,344.00
- Revenue This Year
- OKYO N/A
- DYAI $22.56
- Revenue Next Year
- OKYO N/A
- DYAI $30.95
- P/E Ratio
- OKYO N/A
- DYAI N/A
- Revenue Growth
- OKYO N/A
- DYAI 57.59
- 52 Week Low
- OKYO $0.81
- DYAI $0.93
- 52 Week High
- OKYO $1.98
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- OKYO 60.66
- DYAI 36.18
- Support Level
- OKYO $1.67
- DYAI $0.95
- Resistance Level
- OKYO $1.98
- DYAI $1.13
- Average True Range (ATR)
- OKYO 0.20
- DYAI 0.08
- MACD
- OKYO 0.01
- DYAI 0.00
- Stochastic Oscillator
- OKYO 80.17
- DYAI 20.00
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.